FDA Grants SciSparc Tourette Study
This is a news story, published by MSN, that relates primarily to THC news.
disease research news
For more disease research news, you can click here:
more disease research newsMSN news
For more news from MSN, you can click here:
more news from MSNAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
tetrahydrocannabinol. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest tic severity change news, Yale Global Tic Severity Scale news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Israeli pharma SciSparcSeekingAlpha
•SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate
76% Informative
SCI-110 is a combination of dronabinol, a synthetic form of tetrahydrocannabinol ( THC ) with the endocannabinoid palmitoylethanolamide ( PEA ) The therapy is designed to stimulate cannabinoid receptors across the Central Nervous System .
VR Score
79
Informative language
79
Neutral language
95
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links